From US To EU: Young Biotechs Going It Alone
There Are Several Barriers For A US Biotech To Overcome For A Successful Launch In Europe
Executive Summary
Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.